Table 2 NAC regimens of study patients
Regimen | All (n = 80), n | pCR (n = 26), n (% of all) |
|---|---|---|
Platinum noncontaining regimens | 33 | 7 (21.2) |
AC/EC | 2 | 1 |
AC/EC plus paclitaxel | 19 | 5 |
AC/EC plus docetaxel | 12 | 1 |
Platinum containing regimens | 47 | 19 (40.4) |
Carboplatin + doxorubicin/epirubicin | 6 | 1 |
Carboplatin + docetaxel | 11 | 6 |
Carboplatin + docetaxel + AC/EC | 14 | 7 |
Carboplatin + paclitaxel + AC/EC | 15 | 5 |
Cisplatin + doxorubicin | 1 | 0 |